The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease
Abstract
The presence of the APOE epsilon 4 allele encoding apolipoprotein E4 (apoE4) is the major genetic risk factor for late-onset Alzheimer's disease (AD). However, the molecular and cellular mechanisms by which APOE epsilon 4 renders AD risk are unclear. In this report, we present genetic evidence that an apoE receptor, LRP, may be associated with the expression of late-onset AD. Using a biallelic genetic marker in exon 3 of LRP, late-onset AD cases markedly differed from the control subjects in the distribution of LRP genotypes, and this difference was highly accentuated among AD cases with positive family history of senile dementia. Furthermore, the numbers of neutritic plaques were significantly altered as a consequence of different LRP genotypes in postmortem AD cases. Taken together, our results implicate the pathophysiology of LRP in the expression of late-onset AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Polymorphisms in LRP or α2-macroglobulin increase the risk of late onset familial AD.
“genetic evidence suggests that polymorphisms in either LRP or ␣ 2 -macroglobulin increase the risk of late onset familial AD (35,36).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [35]
Levels of LRP decrease with age.
“Furthermore, levels of LRP decrease with age”
From Increased Extracellular Amyloid Deposition and Neurodegeneration in Human Amyloid Precursor Protein Transgenic Mice Deficient in Receptor-Associated Protein (2002) · cites this paper as Kang et al., 1997
A polymorphism in exon 3 of the LRP gene (C776T) has been associated with increased risk for late onset AD.
“and a polymorphism in exon 3 of the LRP gene (C776T) has been associated with increased risk for late onset AD (Kang et al., 1997(Kang et al., , 2000)).”
From Increased Extracellular Amyloid Deposition and Neurodegeneration in Human Amyloid Precursor Protein Transgenic Mice Deficient in Receptor-Associated Protein (2002) · cites this paper as Kang et al., 1997
Polymorphisms in the LRP and SorLA/LR11 genes have been associated with increased risk for Alzheimer's disease.
“Polymorphisms in the LRP and SorLA/LR11 genes have also been associated with increased risk for Alzheimer's disease [3], [4].”
From Receptor-Associated Protein (RAP) Plays a Central Role in Modulating Aβ Deposition in APP/PS1 Transgenic Mice (2008) · cites this paper as [3]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226
Flagged first, then by citations
Research works printed but not linked: 31
- Schellenberg GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA 1995;92:8552-8559.
- Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;283:4228-4229.
- 10.1073/pnas.90.1.1 · DOI
- Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429-437.
- Castano E, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J 1995;306:599-604.
- LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apoliprotein E to β-amyloid. J Biol Chem 1994;269:23403-23406.
- Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994;264:850-852.
- 10.1073/pnas.92.1.9 · DOI
- Bellosta S, Nathan BP, Orth M, Dong LM, Mahley RW, Pitas RE. Stable expression and secretion of apolipoprotein E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem 1995;270:27063-27071.
- Wolf BB, Lopes MBS, VandenBerg SR, Gonias SL. Characterization and immunohistochemical localization ofα2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol 1992;141:37-42.
- 10.1002/ana.410370703 · DOI
- Strickland DK, Kounnas MZ, Argraves SW. LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J 1995;9:890-898.
- Kounnas MZ, Moir RD, Rebeck GW, et al. LDL-receptor-related protein, a multifunctional apoE receptor, binds secretedβ-amyloid precursor protein and mediated its degradation. Cell 1995;82:331-340.
- Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
- Hansen LA, Galasko D, Samuel W, et al. Apolipoproteinϵ4 is associated with increased neurofibrillary pathology in Lewy body variant of Alzheimer's disease. Neurosci Lett 1994;182:63-65.
- Ozcelik H, Andrulis I. Multiplex PCR-SSCP for simultaneous screening for mutations in several exons of p53. Biotechniques 1995;18:742-744.
- 10.1212/WNL.44.1.1 · DOI
- Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. JAMA 1989;262:2551-2556.
- 10.1126/science.261.5117.9 · DOI
- Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
- Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortices as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
- Beisiegl U, Krapp A, Weber W, Olivecrona G. The role of α 2M receptor/LRP in chylomicron remnant metabolism. Ann NY Acad Sci 1994;737:53-69.
- 10.1038/ng0595-4 · DOI
- Okuizumi K, Onodera O, Namba Y, et al. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nature Genet 1995;11:207-209.
- 10.1016/S0140-6736(96)91551-2 · DOI
- Haines JL, Pritchard ML, Saunders AM, et al. No genetic effect of α1-antichymotrypsin in Alzheimer's disease. Genomics 1996;33:53-56.
- Okuizumi K, Onodera O, Seki K, et al. Lack of association of very low density lipoprotein receptor gene polymorphism with caucasian Alzheimer's disease. Ann Neurol 1996;40:251-254.
- Kerem B-S, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080.
- Van Leuven F, Stas L, Hiliken C, et al. Structure of the gene (LRP1) coding for the human α2-macroglobulin receptor lipoprotein receptor-related protein. Genomics 1994;24:78-89.
- 10.1016/0006-291X(89)91025-5 · DOI
- Johnson SA, McNeil T, Cordell B, Finch CE. Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease. Science 1990;248:854-857.
Cited by
Sorted by citations
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
The molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474
The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease
Miranda, S., Opazo, C., Larrondo, L. F., Muñoz, F. J., Ruiz, F., Leighton, F., & Inestrosa, N. C. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00015-0 · Cited by 369
Kang, D. E., Pietrzik, C. U., Baum, L., Chevallier, N., Merriam, D. E., Kounnas, M. Z., Wagner, S. L., Troncoso, J. C., Kawas, C. H., Katzman, R., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11013 · Cited by 354
Self-citationHoltzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Ling, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
Wilhelmus, M. M. M., Otte-Höller, I., van Triel, J. J. J., Veerhuis, R., Maat-Schieman, M. L. C., Bu, G., de Waal, R. M. W., & Verbeek, M. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070050 · Cited by 138
Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease
Xiong, F., Ge, W., & Ma, C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.006 · Cited by 133
Marzolo, M.-P., & Bu, G. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.10.005 · Cited by 122
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
Thal, D. R., Papassotiropoulos, A., Saido, T. C., Griffin, W. S. T., Mrak, R. E., Kölsch, H., Tredici, K. D., Attems, J., & Ghebremedhin, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0707-9 · Cited by 103
Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures
LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., & Van Eldik, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000602200 · Cited by 103
Van Uden, E., Mallory, M., Veinbergs, I., Alford, M., Rockenstein, E., & Masliah, E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09298.2002 · Cited by 91
Self-citationCurrent knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease
D’Introno, A., Solfrizzi, V., Colacicco, A. M., Capurso, C., Amodio, M., Todarello, O., Capurso, A., Kehoe, P. G., & Panza, F. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.020 · Cited by 23
Xu, G., Karch, C., Li, N., Lin, N., Fromholt, D., Gonzales, V., & Borchelt, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003159 · Cited by 14
Metadata
- Authors
- Kang, D. E., Saitoh, T., Chen, X., Xia, Y., Masliah, E., Hansen, L. A., Thomas, R. G., Thal, L. J., & Katzman, R.
- Venue
- Neurology
- Published
- 1997-07
- Volume
- 49
- Issue
- 1
- Pages
- 56-61
- ISSN
- 0028-3878
- 1526-632X
- Cited by
- 211
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
